PRKDC and prostate carcinoma: Of these genes, DNA-PKc has been found to be significantly upregulated, and treating docetaxel-resistant prostate cancer cells with DNA-PKc specific inhibitors, such as NU7441, LTURM3, and M3814 (which are under clinical investigation), resensitised the cells to docetaxel treatment [170].